Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference
Nemaura Medical, a medical technology firm, announces on September 6, 2022, that CEO Dr. Faz Chowdhury will provide a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference from September 12-14, 2022. The presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET for registered attendees. Nemaura specializes in non-invasive wearable diagnostics, including its sugarBEAT® continuous glucose monitor, with a focus on managing diabetes. The company aims to support metabolic health for a large portion of the population.
- None.
- None.
Loughborough, England, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference, which is being held on September 12 – 14, 2022.
The virtual presentation will be available on-demand beginning on September 12, 2022 at 7:00 a.m. ET to H.C. Wainwright registered attendees of the conference.
Dr. Chowdhury will be available for one-on-one meetings. To request a meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
When is Nemaura Medical's presentation at the H.C. Wainwright Global Investment Conference?
What is Nemaura Medical's focus on glucose monitoring?
What is the sugarBEAT® product by Nemaura Medical?
What markets does Nemaura Medical target?
How can I register for the H.C. Wainwright conference featuring Nemaura Medical?
